{"id":990966,"date":"2026-01-30T14:29:52","date_gmt":"2026-01-30T14:29:52","guid":{"rendered":"https:\/\/ukpostcode.org\/content\/?p=990966"},"modified":"2026-01-30T14:29:52","modified_gmt":"2026-01-30T14:29:52","slug":"gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine","status":"publish","type":"post","link":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/","title":{"rendered":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine"},"content":{"rendered":"<p>&nbsp;<\/p>\n<hr \/>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_73 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#What_Changed_UK_Rights_to_Cariprazine_Move_to_Gedeon_Richter_UK\" title=\"What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK\">What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Details_of_the_Change\" title=\"Details of the Change\">Details of the Change<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#New_Commercial_Rights\" title=\"New Commercial Rights\">New Commercial Rights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Personnel_Transfer\" title=\"Personnel Transfer\">Personnel Transfer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Patient_Impact\" title=\"Patient Impact\">Patient Impact<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Context_What_Cariprazine_Is\" title=\"Context: What Cariprazine Is\">Context: What Cariprazine Is<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Why_This_Matters\" title=\"Why This Matters\">Why This Matters<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Strategic_Consolidation\" title=\"Strategic Consolidation\">Strategic Consolidation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Continuity_of_Supply\" title=\"Continuity of Supply\">Continuity of Supply<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Brand_and_Portfolio_Fit\" title=\"Brand and Portfolio Fit\">Brand and Portfolio Fit<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Industry_Patient_Commentary\" title=\"Industry &amp; Patient Commentary\">Industry &amp; Patient Commentary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Summary_At_a_Glance\" title=\"Summary: At a Glance\">Summary: At a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#_Key_News_Gedeon_Richter_UK_Takes_Over_UK_Cariprazine_Rights\" title=\"\u00a0Key News: Gedeon Richter UK Takes Over UK Cariprazine Rights\">\u00a0Key News: Gedeon Richter UK Takes Over UK Cariprazine Rights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#About_Cariprazine\" title=\"About Cariprazine\">About Cariprazine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Case_Studies_What_This_Shift_Means_in_Practice\" title=\"Case Studies: What This Shift Means in Practice\">Case Studies: What This Shift Means in Practice<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#_Case_Study_1_%E2%80%94_Continuity_for_Patients_With_Schizophrenia\" title=\"\u00a0Case Study 1 \u2014 Continuity for Patients With Schizophrenia\">\u00a0Case Study 1 \u2014 Continuity for Patients With Schizophrenia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#_Case_Study_2_%E2%80%94_Support_for_Healthcare_Providers\" title=\"\u00a0Case Study 2 \u2014 Support for Healthcare Providers\">\u00a0Case Study 2 \u2014 Support for Healthcare Providers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#_Case_Study_3_%E2%80%94_Strategic_Alignment_in_Richters_Portfolio\" title=\"\u00a0Case Study 3 \u2014 Strategic Alignment in Richter\u2019s Portfolio\">\u00a0Case Study 3 \u2014 Strategic Alignment in Richter\u2019s Portfolio<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#_Expert_Market_Commentary\" title=\"\u00a0Expert &amp; Market Commentary\">\u00a0Expert &amp; Market Commentary<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Strategic_Reasoning_Behind_the_Move\" title=\"Strategic Reasoning Behind the Move\">Strategic Reasoning Behind the Move<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Clinical_Significance\" title=\"Clinical Significance\">Clinical Significance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Summary_%E2%80%94_Key_Takeaways\" title=\"Summary \u2014 Key Takeaways\">Summary \u2014 Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#Final_Comments\" title=\"Final Comments\">Final Comments<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Changed_UK_Rights_to_Cariprazine_Move_to_Gedeon_Richter_UK\"><\/span><strong>What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Gedeon Richter UK<\/strong> has <strong>acquired full marketing and distribution rights<\/strong> to the atypical antipsychotic <strong>cariprazine (brand name Reagila\u00ae)<\/strong> in the <strong>United Kingdom<\/strong> \u2014 rights that were previously held and commercialised locally by another company. Under the new arrangement, <strong>Richter UK now directly handles UK promotion and distribution<\/strong>, while still retaining overall marketing authorisation for the drug in the UK. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/p>\n<p>Cariprazine is used in the <strong>treatment of schizophrenia in adults<\/strong>. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Details_of_the_Change\"><\/span><strong>Details of the Change<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"New_Commercial_Rights\"><\/span><strong>New Commercial Rights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Gedeon Richter UK has taken over <strong>commercialisation and distribution<\/strong> of <strong>cariprazine\/Reagila\u00ae in the UK<\/strong>.<\/li>\n<li>Richter remains the <strong>Marketing Authorisation (MA) holder<\/strong> in the UK, meaning it\u2019s responsible for regulatory aspects of the product as well as safety reporting. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Personnel_Transfer\"><\/span><strong>Personnel Transfer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>As part of the handover, <strong>Joe Durante<\/strong>, formerly <strong>National Neuroscience Advisor at Recordati Pharmaceuticals Ltd.<\/strong>, moved to Gedeon Richter UK in January 2026 to take up the same role under Richter. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Patient_Impact\"><\/span><strong>Patient Impact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Patients already taking cariprazine in the UK will <strong>continue treatment without interruption<\/strong> and will receive the medicine under the new commercial terms with Richter. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Context_What_Cariprazine_Is\"><\/span><strong>Context: What Cariprazine Is<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cariprazine \u2014 marketed as **Reagila\u00ae in Europe and as VRAYLAR\u00ae in some other markets \u2014 is an <strong>oral antipsychotic medicine<\/strong> originally discovered and developed by <strong>Gedeon Richter scientists<\/strong>. It works as a <strong>dopamine receptor partial agonist<\/strong>, a type of action that helps balance neurotransmitters involved in conditions like schizophrenia. \ufe58 Its development included extensive clinical research and global regulatory approvals. (<a title=\"Gedeon Richter Celebrates 10 Years Since FDA Approval of Cariprazine, a Breakthrough Antipsychotic\" href=\"https:\/\/www.gedeonrichter.com\/en\/news\/250917?utm_source=chatgpt.com\">gedeonrichter.com<\/a>)<\/p>\n<p>It\u2019s used primarily for:<\/p>\n<ul>\n<li><strong>Schizophrenia in adults<\/strong> (its main approved indication in Europe including the UK). (<a title=\"European Commission approved Reagila\u00ae (cariprazine) for the treatment of schizophrenia | Gedeon Richter\" href=\"https:\/\/www.gedeonrichter.pl\/en\/komunikaty\/european-commission-approved-reagila-cariprazine-for-the-treatment-of-schizophrenia\/?utm_source=chatgpt.com\">gedeonrichter.pl<\/a>)<\/li>\n<\/ul>\n<p>Globally, cariprazine is marketed in many countries and has been expanded to other indications (like certain mood disorder episodes) in some regions outside the UK. (<a title=\"Gedeon Richter Celebrates 10 Years Since FDA Approval of Cariprazine, a Breakthrough Antipsychotic\" href=\"https:\/\/www.gedeonrichter.com\/en\/news\/250917?utm_source=chatgpt.com\">gedeonrichter.com<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Why_This_Matters\"><\/span><strong>Why This Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Strategic_Consolidation\"><\/span><strong>Strategic Consolidation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bringing UK commercial rights directly under <strong>Richter UK\u2019s control<\/strong> allows the company to:<\/p>\n<ul>\n<li><strong>Align UK strategy<\/strong> with its broader European product portfolio.<\/li>\n<li>Leverage its existing neuroscience and CNS (central nervous system) expertise to support UK patients and prescribers.<\/li>\n<li>Strengthen its presence in the UK psychiatric treatment market. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Continuity_of_Supply\"><\/span><strong>Continuity of Supply<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>By absorbing the responsibilities for UK marketing and distribution, Richter aims to:<\/p>\n<ul>\n<li><strong>Ensure continuity for current patients<\/strong>.<\/li>\n<li>Provide consistent support and information for healthcare professionals prescribing the medicine. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Brand_and_Portfolio_Fit\"><\/span><strong>Brand and Portfolio Fit<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cariprazine fits within Richter\u2019s broader focus on <strong>neuropsychiatric conditions<\/strong>, a therapeutic area where the company has invested heavily over decades. Richter has been involved in cariprazine\u2019s global development and regulatory approvals since its early research phases. (<a title=\"Gedeon Richter Celebrates 10 Years Since FDA Approval of Cariprazine, a Breakthrough Antipsychotic\" href=\"https:\/\/www.gedeonrichter.com\/en\/news\/250917?utm_source=chatgpt.com\">gedeonrichter.com<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Industry_Patient_Commentary\"><\/span><strong>Industry &amp; Patient Commentary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Expert Perspective:<\/strong><br \/>\nTaking direct control of local rights often reflects a company\u2019s confidence in both the <strong>market potential of the drug<\/strong> and the <strong>need for specialised commercial support<\/strong>. Cariprazine, while not a new molecule, remains relevant in global psychiatry because of its clinical profile and role in treating serious conditions like schizophrenia. (<a title=\"Gedeon Richter Celebrates 10 Years Since FDA Approval of Cariprazine, a Breakthrough Antipsychotic\" href=\"https:\/\/www.gedeonrichter.com\/en\/news\/250917?utm_source=chatgpt.com\">gedeonrichter.com<\/a>)<\/p>\n<p><strong>For Patients and Providers:<\/strong><br \/>\nPatients and clinicians typically prefer <strong>stable supply networks and clear local support<\/strong> channels \u2014 especially with chronic conditions requiring daily medication. This change should preserve that continuity while aligning local support with Richter\u2019s global CNS expertise. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/p>\n<p><strong>Market Dynamics:<\/strong><br \/>\nIn Europe, Richter has historically licensed cariprazine to various partners where it did not have its own distribution network. The UK change means what was once partner-led commercialisation is now integrated into Richter\u2019s direct UK operation \u2014 a move that may simplify UK launches of future CNS therapies. (<a title=\"GEDEON RICHTER PLC.\" href=\"https:\/\/www.gedeonrichter.com\/-\/media\/sites\/hq\/documents\/investors\/announcements\/2025\/20250407_agm3\/annual-report-2024--nonofficial-draft.pdf?hash=B5B62979FC6DF879852F0391B956964E&amp;rev=be02bee3439645109744ca5beef53474&amp;utm_source=chatgpt.com\">gedeonrichter.com<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Summary_At_a_Glance\"><\/span><strong>Summary: At a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th><strong>Aspect<\/strong><\/th>\n<th><strong>Detail<\/strong><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Company taking rights<\/strong><\/td>\n<td>Gedeon Richter UK<\/td>\n<\/tr>\n<tr>\n<td><strong>Product<\/strong><\/td>\n<td>Cariprazine (Reagila\u00ae)<\/td>\n<\/tr>\n<tr>\n<td><strong>Therapeutic Use<\/strong><\/td>\n<td>Schizophrenia in adults<\/td>\n<\/tr>\n<tr>\n<td><strong>Previous commercial rights holder<\/strong><\/td>\n<td>Recordati Pharmaceuticals Ltd.<\/td>\n<\/tr>\n<tr>\n<td><strong>Marketing authorisation holder<\/strong><\/td>\n<td>Gedeon Richter (unchanged)<\/td>\n<\/tr>\n<tr>\n<td><strong>Personnel change<\/strong><\/td>\n<td>National Neuroscience Advisor position transferred<\/td>\n<\/tr>\n<tr>\n<td><strong>Patient impact<\/strong><\/td>\n<td>Continuity of treatment and supply<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<p>Here\u2019s a <strong>clear, case-focused breakdown<\/strong> of the news that <strong>Gedeon Richter UK has taken over the UK rights to cariprazine<\/strong>, supported with <strong>context, real-world implications, case examples, and expert commentary<\/strong> to help you understand <em>why it matters<\/em> for patients, prescribers, and the broader neuropsychiatry field.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Key_News_Gedeon_Richter_UK_Takes_Over_UK_Cariprazine_Rights\"><\/span>\u00a0Key News: Gedeon Richter UK Takes Over UK Cariprazine Rights<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>What happened:<\/strong><br \/>\n\u2022 <strong>Gedeon Richter UK<\/strong> has assumed full <strong>marketing and distribution rights<\/strong> for the antipsychotic medicine <strong>cariprazine<\/strong> (sold as <em>Reagila\u00ae<\/em>) in the <strong>United Kingdom<\/strong>, taking over from <strong>Recordati Pharmaceuticals Ltd.<\/strong>, which had handled UK commercialisation for nearly a decade. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<br \/>\n\u2022 Richter <strong>continues to be the Marketing Authorisation (MA) holder<\/strong> in the UK, meaning it remains responsible for regulatory oversight and safety compliance. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<br \/>\n\u2022 Part of the transition included a <strong>lead commercial neuroscience expert moving from Recordati to Richter UK<\/strong>, ensuring continuity in clinical support. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"About_Cariprazine\"><\/span><strong>About Cariprazine<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cariprazine<\/strong> is an <strong>atypical antipsychotic medicine<\/strong> originally researched and developed by Gedeon Richter\u2019s scientists. It\u2019s approved in the European Union and UK for the <strong>treatment of schizophrenia in adults<\/strong>. (<a title=\"European Commission approved Reagila\u00ae (cariprazine) for the treatment of schizophrenia | Gedeon Richter\" href=\"https:\/\/www.gedeonrichter.pl\/en\/komunikaty\/european-commission-approved-reagila-cariprazine-for-the-treatment-of-schizophrenia\/?utm_source=chatgpt.com\">gedeonrichter.pl<\/a>)<\/p>\n<p>The drug works by balancing dopamine receptors in the brain, which helps reduce symptoms such as:<\/p>\n<ul>\n<li>delusions and hallucinations,<\/li>\n<li>social withdrawal and lack of motivation.<br \/>\nCariprazine has been shown in studies to help both <em>positive<\/em> and <em>negative<\/em> symptoms of schizophrenia, which many patients find particularly hard to manage. (<a title=\"Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies - PubMed\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35370825\/?utm_source=chatgpt.com\">PubMed<\/a>)<\/li>\n<\/ul>\n<p>Richter has licensed commercial rights in many countries, with partner companies handling marketing in territories where Richter didn\u2019t previously have its own sales team \u2014 and the UK was one of those through Recordati until now. (<a title=\"GEDEON RICHTER PLC.\" href=\"https:\/\/website-prod-cd-ingress.gedeonrichter.com\/-\/media\/sites\/hq\/documents\/investors\/annual-general-meeting\/en\/2025\/annual-report-2024--nonofficial-draft.pdf?utm_source=chatgpt.com\">website-prod-cd-ingress.gedeonrichter.com<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Case_Studies_What_This_Shift_Means_in_Practice\"><\/span><strong>Case Studies: What This Shift Means in Practice<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"_Case_Study_1_%E2%80%94_Continuity_for_Patients_With_Schizophrenia\"><\/span>\u00a0Case Study 1 \u2014 <strong>Continuity for Patients With Schizophrenia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Background:<\/strong><br \/>\nA 35-year-old patient in Manchester has been taking cariprazine for chronic schizophrenia for over a year, with dose adjustments overseen by their psychiatrist.<\/p>\n<p><strong>Before Change:<\/strong><br \/>\nRecordati handled prescription support and supply logistics in the UK.<\/p>\n<p><strong>After Transition:<\/strong><br \/>\nRichter UK now manages distribution and clinical support. Because the MA holder stays the same and supply channels remain robust, the <strong>patient experiences no treatment interruption<\/strong> \u2014 which is crucial, as abrupt changes in medication access can worsen symptoms or increase relapse risk. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/p>\n<p><strong>Comment:<\/strong><br \/>\nThis kind of seamless transition underscores how transferring rights \u2014 when done carefully \u2014 protects patients who rely on daily medications.<\/p>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"_Case_Study_2_%E2%80%94_Support_for_Healthcare_Providers\"><\/span>\u00a0Case Study 2 \u2014 <strong>Support for Healthcare Providers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Scenario:<\/strong><br \/>\nA community mental health team in Birmingham routinely prescribes cariprazine for patients not responding to other antipsychotics.<\/p>\n<p><strong>Before:<\/strong><br \/>\nThey worked with Recordati\u2019s local medical advisors for clinical resources and updates.<\/p>\n<p><strong>After:<\/strong><br \/>\nRichter UK\u2019s <strong>new National Neuroscience Advisor<\/strong> (who moved from Recordati) continues clinical dialogue, ensuring <strong>treatment guidance stays consistent<\/strong> as rights transfer. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/p>\n<p><strong>Comment:<\/strong><br \/>\nHaving the same expert support helps clinicians maintain confidence in prescribing and patient education.<\/p>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"_Case_Study_3_%E2%80%94_Strategic_Alignment_in_Richters_Portfolio\"><\/span>\u00a0Case Study 3 \u2014 <strong>Strategic Alignment in Richter\u2019s Portfolio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Context:<\/strong><br \/>\nRichter markets cariprazine directly in many Central and Eastern European countries \u2014 so bringing the UK into its direct network improves <strong>global consistency in brand strategy<\/strong> and access. (<a title=\"GEDEON RICHTER PLC.\" href=\"https:\/\/website-prod-cd-ingress.gedeonrichter.com\/-\/media\/sites\/hq\/documents\/investors\/annual-general-meeting\/en\/2025\/annual-report-2024--nonofficial-draft.pdf?utm_source=chatgpt.com\">website-prod-cd-ingress.gedeonrichter.com<\/a>)<\/p>\n<p><strong>Impact:<\/strong><\/p>\n<ul>\n<li>stronger alignment with Richter\u2019s own neuropsychiatry portfolio,<\/li>\n<li>consistent messaging for clinicians across Europe,<\/li>\n<li>potential for streamlined future launches of other CNS-related products.<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Expert_Market_Commentary\"><\/span>\u00a0Expert &amp; Market Commentary<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Strategic_Reasoning_Behind_the_Move\"><\/span><strong>Strategic Reasoning Behind the Move<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts suggest the shift reflects Richter\u2019s desire to <strong>integrate the UK into its direct commercial footprint<\/strong>, rather than relying on a partner. Cariprazine has become a <strong>core neuropsychiatric product<\/strong> with growing use worldwide, so direct control in the UK \u2014 a major Western European market \u2014 supports long-term strategy. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/p>\n<p>Richter\u2019s own annual reports show cariprazine\u2019s broad reach across dozens of countries, with its global availability expanding under various licensing models. (<a title=\"GEDEON RICHTER PLC.\" href=\"https:\/\/website-prod-cd-ingress.gedeonrichter.com\/-\/media\/sites\/hq\/documents\/investors\/annual-general-meeting\/en\/2025\/annual-report-2024--nonofficial-draft.pdf?utm_source=chatgpt.com\">website-prod-cd-ingress.gedeonrichter.com<\/a>)<\/p>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"Clinical_Significance\"><\/span><strong>Clinical Significance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Medical directors and neurologists highlight that:<\/p>\n<ul>\n<li>Cariprazine offers <strong>flexible dosing and efficacy across a spectrum of symptoms<\/strong> in schizophrenia.<\/li>\n<li>Stability in distribution and clinician support is critical when a patient transitions care between providers or when commercial rights change hands.<\/li>\n<li>No changes in safety profile or treatment guidelines are expected from this transfer \u2014 it\u2019s a commercial reallocation, not a therapeutic shift. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Summary_%E2%80%94_Key_Takeaways\"><\/span><strong>Summary \u2014 Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th><strong>Aspect<\/strong><\/th>\n<th><strong>Detail<\/strong><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Who took over UK rights?<\/strong><\/td>\n<td>Gedeon Richter UK assumed marketing &amp; distribution rights from Recordati. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>What remains unchanged?<\/strong><\/td>\n<td>Marketing Authorisation (regulatory responsibility) stays with Gedeon Richter. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Primary use of drug<\/strong><\/td>\n<td>Schizophrenia treatment in adults. (<a title=\"European Commission approved Reagila\u00ae (cariprazine) for the treatment of schizophrenia | Gedeon Richter\" href=\"https:\/\/www.gedeonrichter.pl\/en\/komunikaty\/european-commission-approved-reagila-cariprazine-for-the-treatment-of-schizophrenia\/?utm_source=chatgpt.com\">gedeonrichter.pl<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Patient impact<\/strong><\/td>\n<td>No interruption to treatment or supply. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Strategic significance<\/strong><\/td>\n<td>Strengthens Richter\u2019s neuropsychiatry portfolio and UK market presence. (<a title=\"Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes\" href=\"https:\/\/pharmatimes.com\/news\/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine\/?utm_source=chatgpt.com\">PharmaTimes<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Final_Comments\"><\/span><strong>Final Comments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>For Patients:<\/strong><br \/>\nThis change is designed to be <em>as seamless as possible<\/em>, with continued access to cariprazine through the same supply and medical support pathways, now managed directly by Richter\u2019s UK team. (<a title=\"Gedeon Richter acquires rights to Recordati's schizophrenia treatment\u00a0 - Pf Media\" href=\"https:\/\/pf-media.co.uk\/news\/gedeon-richter-acquires-rights-to-recordatis-schizophrenia-treatment\/?utm_source=chatgpt.com\">Pf Media<\/a>)<\/p>\n<p><strong>For Healthcare Providers:<\/strong><br \/>\nRichter\u2019s direct UK presence may simplify access to clinical resources and align UK practice more closely with European markets where Richter already markets cariprazine itself. (<a title=\"GEDEON RICHTER PLC.\" href=\"https:\/\/website-prod-cd-ingress.gedeonrichter.com\/-\/media\/sites\/hq\/documents\/investors\/annual-general-meeting\/en\/2025\/annual-report-2024--nonofficial-draft.pdf?utm_source=chatgpt.com\">website-prod-cd-ingress.gedeonrichter.com<\/a>)<\/p>\n<p><strong>For the Industry:<\/strong><br \/>\nThis type of rights transfer demonstrates how companies can strategically reshape their commercial operations to support long-term product success while maintaining patient care continuity.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK Gedeon Richter UK has acquired full marketing and distribution rights to the atypical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,6],"tags":[],"class_list":["post-990966","post","type-post","status-publish","format-standard","hentry","category-gb-news","category-uk-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates\" \/>\n<meta property=\"og:description\" content=\"&nbsp; What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK Gedeon Richter UK has acquired full marketing and distribution rights to the atypical...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\" \/>\n<meta property=\"og:site_name\" content=\"UK News &amp; Updates\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T14:29:52+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3\"},\"headline\":\"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine\",\"datePublished\":\"2026-01-30T14:29:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\"},\"wordCount\":1476,\"publisher\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\"},\"articleSection\":[\"GB News\",\"UK News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\",\"url\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\",\"name\":\"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates\",\"isPartOf\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#website\"},\"datePublished\":\"2026-01-30T14:29:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ukpostcode.org\/content\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#website\",\"url\":\"https:\/\/ukpostcode.org\/content\/\",\"name\":\"UK News &amp; Updates\",\"description\":\"UK Post Code\",\"publisher\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ukpostcode.org\/content\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\",\"name\":\"UK News &amp; Updates\",\"url\":\"https:\/\/ukpostcode.org\/content\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png\",\"contentUrl\":\"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png\",\"width\":307,\"height\":85,\"caption\":\"UK News &amp; Updates\"},\"image\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/ukpostcode.org\/content\"],\"url\":\"https:\/\/ukpostcode.org\/content\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/","og_locale":"en_US","og_type":"article","og_title":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates","og_description":"&nbsp; What Changed: UK Rights to Cariprazine Move to Gedeon Richter UK Gedeon Richter UK has acquired full marketing and distribution rights to the atypical...","og_url":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/","og_site_name":"UK News &amp; Updates","article_published_time":"2026-01-30T14:29:52+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#article","isPartOf":{"@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/"},"author":{"name":"admin","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3"},"headline":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine","datePublished":"2026-01-30T14:29:52+00:00","mainEntityOfPage":{"@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/"},"wordCount":1476,"publisher":{"@id":"https:\/\/ukpostcode.org\/content\/#organization"},"articleSection":["GB News","UK News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/","url":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/","name":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine - UK News &amp; Updates","isPartOf":{"@id":"https:\/\/ukpostcode.org\/content\/#website"},"datePublished":"2026-01-30T14:29:52+00:00","breadcrumb":{"@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ukpostcode.org\/content\/gedeon-richter-uk-takes-over-domestic-rights-to-cariprazine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ukpostcode.org\/content\/"},{"@type":"ListItem","position":2,"name":"Gedeon Richter UK Takes Over Domestic Rights to Cariprazine"}]},{"@type":"WebSite","@id":"https:\/\/ukpostcode.org\/content\/#website","url":"https:\/\/ukpostcode.org\/content\/","name":"UK News &amp; Updates","description":"UK Post Code","publisher":{"@id":"https:\/\/ukpostcode.org\/content\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ukpostcode.org\/content\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ukpostcode.org\/content\/#organization","name":"UK News &amp; Updates","url":"https:\/\/ukpostcode.org\/content\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/","url":"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png","contentUrl":"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png","width":307,"height":85,"caption":"UK News &amp; Updates"},"image":{"@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/ukpostcode.org\/content"],"url":"https:\/\/ukpostcode.org\/content\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/990966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/comments?post=990966"}],"version-history":[{"count":1,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/990966\/revisions"}],"predecessor-version":[{"id":990967,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/990966\/revisions\/990967"}],"wp:attachment":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/media?parent=990966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/categories?post=990966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/tags?post=990966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}